Temozolomide

Primary Uses

Temozolomide is an alkylating agent used to treat certain forms of brain cancer. It is specifically approved for the following conditions in adults:

• Newly Diagnosed Glioblastoma Multiforme: For this type of aggressive brain tumor, temozolomide is typically used in combination with radiotherapy. Following the completion of radiation, it is often continued alone as a maintenance treatment.
• Refractory Anaplastic Astrocytoma: This medication is used to treat patients with anaplastic astrocytoma whose tumors have returned or continued to grow after previous chemotherapy treatments.

Temozolomide works by slowing or stopping the growth of cancer cells in the body. It is available in both oral capsule form and as an intravenous (IV) injection, depending on the patient's needs and the healthcare provider's recommendation.

Mechanism of Action

Temozolomide belongs to a class of medications known as alkylating agents. It is used to treat specific types of brain tumors by disrupting the way cancer cells grow and spread throughout the body.

The medication works through the following process:

• Activation: Once the drug enters the body, it is converted into an active substance that can target the genetic material inside cells.
• DNA Damage: The active form of the drug attaches to the DNA (the genetic blueprint) of cancer cells. This creates damage that prevents the cells from being able to read or copy their genetic code correctly.
• Inhibiting Cell Division: Because the cancer cells cannot replicate their DNA, they are unable to divide and create new cells.

Cancer cells generally divide much faster than healthy cells, making them more susceptible to this type of treatment. When these cells are unable to multiply, they eventually die, which helps to shrink the tumor or prevent it from getting larger.

Common Side Effects

The most frequently reported side effects of temozolomide include:

• Nausea and vomiting
• Constipation
• Loss of appetite
• Fatigue and generalized weakness
• Headache
• Dizziness
• Hair loss
• Trouble sleeping

Serious Side Effects

Seek medical attention immediately if you notice any of the following serious symptoms:

• Signs of infection: Fever, chills, sore throat, or other flu-like symptoms.
• Easy bruising or bleeding: Unexplained bruising, nosebleeds, or bleeding that will not stop.
• Liver issues: Yellowing of the skin or eyes, dark-colored urine, or severe stomach pain.
• Respiratory problems: Shortness of breath, wheezing, or a persistent dry cough.
• Allergic reactions: Skin rash, hives, or swelling of the face, lips, or throat.

This medication can significantly lower blood cell counts, which may lead to serious infections or bleeding problems. It may also increase the risk of developing certain secondary cancers or cause severe liver damage. Regular monitoring by a healthcare professional is required to manage these risks.

Myelosuppression

Temozolomide can cause a significant decrease in blood cell counts, particularly white blood cells (neutropenia) and platelets (thrombocytopenia). Severe myelosuppression can lead to serious infections or bleeding. Blood counts are typically monitored weekly during the first cycle and at specific intervals in subsequent cycles to ensure they remain within a safe range.

Pneumocystis jirovecii Pneumonia (PJP)

There is an increased risk of developing PJP, a serious type of pneumonia, when taking temozolomide. This risk is notably higher for patients receiving the drug alongside radiation therapy or steroids. Healthcare providers may prescribe preventative medication to reduce this risk during certain phases of treatment.

Hepatotoxicity

Liver injury, including cases of fatal liver failure, has been reported in patients taking temozolomide. Liver function tests are usually performed before starting treatment, after each treatment cycle, and periodically throughout therapy to monitor for signs of damage.

Secondary Malignancies

Treatment with temozolomide may increase the long-term risk of developing secondary cancers, such as myelodysplastic syndrome (MDS) or myeloid leukemia.

Embryo-Fetal Toxicity

Temozolomide can cause harm to an unborn baby. Effective birth control is recommended for females of reproductive potential during treatment and for a specific period after the final dose. Males with female partners of reproductive potential should also use effective contraception, as the drug can affect sperm and fetal development.

Contraindications

This medication should not be used by individuals who have a known history of severe hypersensitivity reactions to temozolomide or dacarbazine (DTIC), as these drugs are chemically similar.

Pregnancy

Temozolomide can cause fetal harm and birth defects when administered to a pregnant woman. It is considered genotoxic and embryotoxic. Patients should discuss the risks and benefits of treatment with their healthcare provider if they are pregnant or planning to become pregnant.

Effective contraception is required for both men and women during and after treatment:

• Females: Women of reproductive potential should use effective birth control during treatment and for at least 6 months after the last dose.
• Males: Men with female partners who can become pregnant should use effective contraception during treatment and for at least 3 months after the last dose. Men should also avoid donating sperm during this period.

Breastfeeding

There is no information regarding the presence of temozolomide in human milk or its effects on the breastfed child. Because of the potential for serious adverse reactions in a nursing infant, it is recommended that breastfeeding be discontinued during treatment and for at least 1 week after the final dose.

Available Forms

Temozolomide is produced in two primary delivery formats:

• Oral Capsules: These are taken by mouth. They must be swallowed whole and should not be opened, crushed, or chewed.
• Intravenous Injection: This form is supplied as a powder in a single-dose vial. A healthcare professional reconstitutes the powder into a solution for administration as an infusion into a vein.

FDA Approval and Indications

Temozolomide is an alkylating agent that received FDA approval for the treatment of specific brain cancers. Its approved indications include:

• Newly Diagnosed Glioblastoma Multiforme (GBM): It is used in combination with radiotherapy and then as a single-agent maintenance treatment.
• Refractory Anaplastic Astrocytoma: It is indicated for adults whose tumors have progressed after treatment with a chemotherapy regimen containing a nitrosourea and procarbazine.

Available Formulations

The FDA has approved temozolomide in two delivery formats: oral capsules and an intravenous (IV) infusion. The intravenous form is approved for use as an alternative for patients who are unable to take the medication by mouth. Both formulations are considered bioequivalent, meaning they deliver the same amount of active drug to the body.

Regulatory Warnings and Monitoring

While temozolomide does not require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA-approved labeling contains significant warnings regarding serious side effects. These include:

• Myelosuppression: A severe decrease in blood cell counts (neutrophils and platelets) that can lead to infection or bleeding.
• Hepatotoxicity: Potential for severe liver injury, including liver failure.
• Pneumocystis jirovecii pneumonia (PJP): Increased risk of this specific type of pneumonia, particularly when used with radiation.

Regulatory guidelines require healthcare providers to monitor blood counts and liver function tests regularly throughout the course of treatment.

Types of Cancer Treated

Temozolomide is specifically indicated for the treatment of certain brain tumors in adults:

• Glioblastoma multiforme: For newly diagnosed cases, it is typically used alongside radiation therapy and then continued alone as maintenance treatment.
• Anaplastic astrocytoma: It is used for patients whose cancer has returned or progressed after previous chemotherapy treatments (refractory).

How It Works

As an alkylating agent, temozolomide works by damaging the DNA of cancer cells. This interference prevents the cells from dividing and growing, which helps to shrink tumors or slow their progression.

The medication is available in both oral capsules and as an intravenous injection. The choice of administration depends on the patient's specific treatment plan and medical needs. Because it can cross the blood-brain barrier, it is particularly effective for treating tumors located in the brain.